Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 4Breast 1

Conditions

Neoplasms 5Prostatic Neoplasms, Castration-Resistant 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × xentuzumab × Clear all
NCT01403974 2025-07-25

Phase I Trial of BI 836845 for Various Solid Cancer

Boehringer Ingelheim

Phase 1 Completed
61 enrolled 33 charts
Tumor-Agnostic

Neoplasms

NCT02123823 2025-07-15

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Boehringer Ingelheim

Phase 1 Completed
164 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01317420 2025-07-11

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

Boehringer Ingelheim

Phase 1 Completed
64 enrolled 27 charts
Tumor-Agnostic

Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Boehringer Ingelheim

Phase 1 Completed
133 enrolled 26 charts
Breast

Breast Neoplasms, Neoplasms

NCT02145741 2025-06-19

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
21 enrolled 9 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡